RC1416 not checked

Nanjing RegeneCore Biotech Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
4 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“There are two doses in this part. Each subjects will receive the drug by subcutaneous injection.”In the company’s words, NCT07403487 on ClinicalTrials.gov
Tested for
Moderate to Severe Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Main trialPhase 2
“This study is a phase II study of RC1416 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of RC1416 in subjects with severe uncontrolled asthma.”In the company’s words, NCT07403487 on ClinicalTrials.gov

Other drugs for Moderate to Severe Asthma

All 58 drugs for Moderate to Severe Asthma

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 25 Oct 2027 Phase II Trial of RC1416 Injection in Asthma
Phase 2Recruiting 31 May 2028 Phase II Study of RC1416 Injection in COPD
Phase 1Completed 14 May 2024 A Phase I Study of RC1416 Injection
Phase 1Completed 25 Sep 2025 A Phase Ib Study of RC1416 Injection
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow RC1416

Following is part of Solo: you see every change to RC1416 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in